Denosumab: In the prevention of skeletal-related events in patients with bone metastases from solid tumours

Drugs

Volumn 71, Issue 8, 2011, Pages 1059-1069

  Scott, Lesley J ^a   Muir, Victoria J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Bone metastases; Cancer; Denosumab; General

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; ASTHENIA; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE TURNOVER; BREAST CANCER; CANCER GROWTH; CANCER RISK; CLINICAL TRIAL (TOPIC); COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FRACTURE; HEADACHE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JAW OSTEONECROSIS; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOLYSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SOLID TUMOR; SPINAL CORD COMPRESSION;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79958850341     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11207370-000000000-00000     Document Type: Article

References (28)

1. Coleman RE, Guise TA, Lipton A, et al. Advancing treatment for metastatic bone cancer: consensus recommendations fromthe Second Cambridge Conference. Clin Cancer Res 2008; 14 (20): 6387-95.
2. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008; 98 (11): 1736-40. (Pubitemid 351748847)
3. Janjan N. Bone metastases: approaches to management. Sem Oncol 2001; 28 (4 Suppl. 11): 28-34. (Pubitemid 32844926)
4. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29 (2): 155-92. (Pubitemid 351519689)
5. Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone 2011; 48 (1): 96-9.
6. Amgen Incorporated. XGEVA (denosumab) injection, for subcutaneous use: US prescribing information [online]. Available from URL: http://pi.amgen.com/ united-states/xgeva/xgeva-pi.pdf [Accessed 2011 Feb 3].
7. Amgen Incorporated. FDA approves Amgen's XGEVA (TM) for the prevention of skeletal-related events in patients with bone metastases from solid tumours [online]. 2010. Available fromURL: http://www.amgen.com/media/media-pr-detail. jsp?releaseID=1498709 [Accessed 2011 May 3].
8. European Medicines Agency. Prolia (denosumab) summary of product characteristics [online]. Available from URL: http://www.amgen.com/pdfs/en- prolia-approved-pi-maa.pdf [Accessed 2010 May 31].
9. Amgen Incorporated. Prolia (denosumab) prescribing information [online]. Available from URL: http://pi.amgen.com/united-states/prolia/prolia-pi.pdf [Accessed 2010 Jun 6].
10. Muir VJ, Scott LJ.Denosumab: in cancer treatment-induced bone loss. Biodrugs 2010; 24 (6): 379-86.
11. Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011; 28 (1): 63-82.
12. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24 (2): 182-95.
13. Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009; 24 (2): 196-208.
14. Stopeck AT, Lipton A, Body J-J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28 (35): 5132-9.
15. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377 (9768): 813-22.
16. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29 (9): 1125-32.
17. Lipton A, Steger GG, Figueroa J, et al. Randomized activecontrolled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25 (28): 4431-7. (Pubitemid 350013849)
18. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27 (10): 1564-71.
19. Body J-J, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12 (4): 1221-8. (Pubitemid 43342512)
20. Coleman R, Brown J, Terpos E, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008; 34 (7): 629-39.
21. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14 (20): 6690-6.
22. Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009; 182 (2): 509-15; discussion 515-6.
23. Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008; 99 (6): 1237-42. (Pubitemid 351676637)
24. Fallowfield L, Patrick D, Body J, et al. Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: results from a randomized phase III trial [abstract no. 1025]. J Clin Oncol 2010; 28 (15 Suppl.): 1025.
25. Lipton A, Siena S, Rader M, et al. Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials [abstract no. 1249P]. Ann Oncol 2010; 21 Suppl. 8: viii380.
26. Novartis Pharmaceuticals Corporation. Zometa- (zoledronic acid): US prescribing information [online]. Available from URL: http://www.pharma.us. novartis.com/product/pi/pdf/ Zometa.pdf [Accessed 2011 May 3].
27. Stopeck A, MartinM, Ritchie D, et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase [abstract no. P6-14-01]. 33rd Annual San Antonio Breast Cancer Symposium; 2010 Dec 8-12; San Antonio (TX).
28. European Medicines Agency. XGEVA [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002173/smops/Positive/human-smop-000225.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d127 [Accessed 2011 May 26]